Viking Therapeutics (GB:0VQA)
LSE:0VQA
0VQA Stock Chart & Stats
$35.53
-$1.82(-4.29%)
At close: 4:00 PM EST
$35.53
-$1.82(-4.29%)
Day’s Range― - ―
52-Week Range$21.57 - $59.06
Previous CloseN/A
Volume9.12K
Average Volume (3M)25.25K
Market Cap
$4.05B
Enterprise Value$3.93B
Total Cash (Recent Filing)$705.74M
Total Debt (Recent Filing)$137.00K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Apr 29, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding115,554,300
10 Day Avg. Volume20,330
30 Day Avg. Volume25,248
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-41.82K
Enterprise Value/Ebitda-10.00
Forecast
1Y Price Target
$93.00Price Target Upside161.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressCompletion of enrollment in both pivotal Phase III trials and a fully enrolled maintenance study signals strong program momentum and supports advancement toward regulatory data readouts and commercialization planning.
Commercial DifferentiationA highly tolerable safety profile, planned auto-injector convenience, and confidence in manufacturing capacity support competitive positioning and multiple routes to market beyond traditional payer channels.
Product StrategyOffering injectable and oral versions of the same active molecule could simplify transitions between induction and maintenance therapy and reduce barriers that arise when patients must switch drugs.
Bears Say
Clinical Timeline RiskExtended timelines for large late-stage trials and staggered oral and injectable programs prolong the wait for definitive efficacy and regulatory decisions, delaying commercialization clarity.
Financial And Competitive PressureRising research and development spending, recent financial misses, and ongoing manufacturing and competitive challenges increase the likelihood of future funding needs and potential shareholder dilution.
Maintenance Efficacy RiskMeaningful weight regain or high discontinuation rates in the maintenance study would weaken confidence in long-term effectiveness and could materially harm investor sentiment.
Viking Therapeutics News
0VQA FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest share price was $21.57 and its highest was $59.06 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $4.05B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Apr 29, 2026 which is in 13 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Feb 11, 2026. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.89 by -$0.49.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.98.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 115,554,300 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.89. Following the earnings report the stock price went up 8.188%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in GB:0VQA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.00 (161.75% Upside)
$93.00 (161.75% Upside)
Blogger Sentiment
Bullish
GB:0VQA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $149.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.56%
12-Months-Change
Fundamentals
Return on Equity
-48.04%
Trailing 12-Months
Asset Growth
-21.20%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
0VQA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.View all GB:0VQA earnings summaries0VQA Stock 12 Month Forecast
Average Price Target
$93.00
▲(161.75% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Options Prices
Currently, No data available
---